Cardiovascular events post cannabis abuse during the COVID-19 pandemic

Irini Kotsalou1*, Georgios Mantonanakis2, Athanasios Kotsalos3, Georgios Koniaris1, Athanasios Zafeirakis1, Nikolaos Dimakopoulos3

1 Nuclear Medicine Department, NIMTS Veterans Hospital, Athens, Greece
2 Agricultural University of Athens, Greece
3 Cardiovascular Department, NIMTS Veterans Hospital, Athens, Greece

* Corresponding Author: Irini Kotsalou E-mail: kotsiren@otenet.gr

ABSTRACT

Objective: The pandemic caused by Sars-CoV-2 (COVID-19) has changed dramatically individuals’ life worldwide. The implication of measures of public health protection, the social distance and isolation, the lockdown and the decrease of social life activities caused escalated anxiety, depression, physical inactivity on the one hand and widespread unemployment and financial crisis on the other hand. Preliminary studies during COVID-19 pandemic reported an increase in the use of psychoactive substances, including alcohol and cannabis (CB). The latter has been linked with harmful cardiovascular and respiratory effects (eg. lung cancer, bronchitis and pulmonary emphysema). Especially people with substance use disorders were further stressed by the current circumstances and were found to intensify consumption of cannabinoids (1-4). This short review focuses on the possible cardiovascular impact of CB abuse in the era of Covid-19 pandemic. It aims to stress the worldwide clinical attention and the clinicians’ awareness on the development of specific prevention and intervention strategies against CB addiction during pandemics.

Keywords: pandemic, psychoactive substances, marijuana, cannabis, cardiovascular, coronary syndrome, myocardial infarct, Sars-CoV-2, COVID-19

INTRODUCTION

The last decades many countries and states have legalized marijuana’s (MJ) use and other cannabinoids for medical and recreational purposes. MJ derived from the hemp plant Cannabis sativa is the most commonly abused psychoactive drug around the privileged world and about 11.8 million young individuals in the United States report MJ use with a dramatic increase of consumption rates among all age groups (5, 6). Furthermore, nowadays these drugs are even more available and accessible to people stressed by the COVID-19 crisis which results on few systemic acute and long term side effects. Literature data report that serious adverse events of cannabinoids include myocardial infarction (MI), sudden cardiac death, cardiomyopathy, stroke, transient ischemic attack, and CB arteritis, vascular diseases (coronary, cerebral and peripheral), arrhythmias and stress cardiomyopathy to be the less investigated. Many of the victims of these disorders are young men with almost none cardiovascular risk factor. As MJ has become extremely prevalent in our society, the prevention of acute cardiovascular events post MJ use requires collaboration among cardiologists, drug users and addiction experts (7, 8).

Cardiovascular effects of cannabinoids (CB)

Physiology

The current available literature associates MJ with several serious adverse cardiovascular disease (CVD) events, due the interaction of cannabinoids with the endogenous endocannabinoid system with different mechanisms like “CB arteritis.” CB- induced vasospasms and platelet aggregation (9, 10). The French Addictovigilance Network (during 2006-2010) reported that only 2% of all CB related events were proved to be CVD side effects, including mainly acute coronary syndromes and peripheral arteriopathies (11).
Nevertheless, reports associate the increased frequency of MJ use with the risk of cardiac arrhythmias and MI, whereas the chronic cannabinoids use has been directly linked with increased angina frequency, due to a decrease in the angina threshold, diminished sympathetic and parasympathetic nervous system (NS) signal transduction, serum aldosterone increase, central and peripheral vasoconstriction, and hypertension (7). Most of the CVD effects of cannabinoids are mediated through the subsequent activation of the sympathetic NS and the inhibition of the parasympathetic autonomic NS (12). Thus, CB smoking increases the heart rate, the serum norepinephrine level and myocardial oxygen demand immediately, it reduces oxygen supply and leads to pro-coagulant or pro-thrombotic state, while the increased atriope inhibits the parasympathetic activity (12-17).

According to recent reports, the CB use might also cause dose-dependent elevation of the systolic blood pressure and heart rate (18, 19) and induce atrial fibrillation shortly after smoking MJ (20). While smoking CB, the oxygen delivery to the heart and other vital organs is diminished and the carboxyhemoglobin levels are elevated, resulting in reduce of the time to onset of symptoms during exercise in patients with stable angina (12).

Complications of MJ abuse

1. Acute Coronary Syndrome (ACS): The CB use is found to increase fivefold the risk for ACS within a 5 hours window post abuse, whereas the reintroduction of MJ abuse is directly correlated with recurrence of the syndrome (12, 21), and this risk dramatically declines after the first hour of exposure to MJ (22, 23). Moreover, these acute MI events are associated with higher short-term mortality in CB users, perhaps due to the analgesic effect of MJ on anginal symptoms (14).

Several case reports indicate the coronary vasospasm-induced cardiomyopathy as the principal effect of CB abuse (24-29), whereas most of them are patients without CVD history or related risk factors. The majority of these individuals presented at the Emergency Departments with ACS after MJ use, with ST-segment elevation in their Electrocardiogram (ECG) and increased cardiac enzymes and were subjected to cardiac magnetic resonance imaging or coronary angiography which were finally negative for occlusive atherosclerotic disease (12, 21), indicating the coronary vasospasm as the most possible cause of these CVD events (24). Retrospective systematic review of published articles showed ST segment elevation in 60% of EKGs, 36.8% of patients had normal coronary arteries, 35% had LAD coronary artery occlusion and 34% of cases had concomitant cardiomyopathy compared to non-users (30-32).

In other cases, coronary angiogram revealed occlusive thrombus inside the coronary artery which was attributed to non-reversible platelet aggregation due to CB use (10, 33). The possible mechanism is that the CB use inhibits the parasympathetic system, induces an inflammatory effect in the arterial wall, which leads in endothelial erosion due to oxidative stress, plaque rupture, factor VII activation and finally to thrombus formation (23, 34, 35).

Also, MJ smoking is proven to decrease the maximum exercise capacity in healthy individuals, while the cutoff of angina threshold is lowered when comparing individuals with MJ smoking and nicotine smoking. The exercise time to angina post MJ smoking is reduced by an average of 48% as compared to 23% after tobacco cigarette smoking, indicating that the increase in cardiac events was independent of tobacco use (22).

On the contrary, cardiovascular mortality in patients with known CAD is increased by 3-fold especially after MI in MJ users compared to non MJ users (22). A meta-analysis on non-fatal MI related to the CB smoking indicated the MJ abuse as the third-highest-ranking associated variable (Hata! Başvuru kaynağı bulunamadı.).

2. Left Ventricular Systolic Dysfunction: Besides, cannabinoids were found to reduce myocardial contractility, whereas this systolic dysfunction might result from persistent tachycardia, atrial fibrillation or ischemia in the case with pre-existing CAD (12).

Adrenergic stimulation causes a reduction in action potential duration and results in a microreentrant tachycardia (17). Serious ventricular arrhythmias shortly after CB smoking may cause dizziness, syncope, cardiac arrest or even sudden cardiac death, due to acute myocardial microvascular spasm, acute MI, or pre-existing CAD (12, Hata! Başvuru kaynağı bulunamadı.). Thus, research studies found that MJ use is associated with a three-fold higher mortality rate after MI, with higher mortality rate among CB users with MI compared to non-users (39).

Author Contributions: IK, GM, AK, GK, AZ, ND: Study design literature search and Data collection, IK: Article writing and revisions.

Financial & competing interest’s disclosure: The authors have no relevant affiliations or financial involvement with any organisation or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Ethical approval: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by Local Ethical Committee.

Conflict of interest: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. This research did not receive and specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
REFERENCES

1. Borgonhi EM, Volpatto VL, Ornell F, Rabelo-da-Ponte FD, Paim Kessler FH. Multiple clinical risks for CB users during the COVID-19 pandemic. Addict Sci Clin Pract. 2021;16:5 https://doi.org/10.1186/s13722-021-00214-0

2. Satre DD, Irrulare E, Ghadiali M, Young-Wolf KC, Campbell CI, Leibowitz AS, et al. Treatment for anxiety and substance use disorders during the COVID-19 pandemic: challenges and strategies. J Addict Med. 2020;14(6):e293–6. https://doi.org/10.1097/ADM.0000000000000755.

3. Dumas TM, Ellis W, Litt DM. What does adolescent substance use look like during the COVID-19 pandemic? Examining changes in frequency, social contexts, and pandemic-related predictors. J Adolesc Heal. 2020;67(3):354–61.

4. Avena NM, Simkus J, Lewandowski A, Gold MS, Marc N. Potenza. Substance Use Disorders and Behavioral Addictions During the COVID-19 Pandemic and COVID-19-related Restrictions. Front. Psychiatry doi: 10.3389/fpsyt.2021.653674

5. Substance Abuse and Mental Health Services Administration (SAMHSA). Results from the 2018 National Survey on Drug Use and Health: Detailed Tables. Available online: https://www.samhsa.gov/data/report/2018-NSDUH-Detailed-Tables (accessed on 14 December 2019).

6. Azofeifa A, Mattson M.E, Schauer G, McAfee T, Grant A, Lyerla, R. National estimates of MJ use and related indicators—National Survey on Drug Use and Health, United States, 2002–2014. MMWR Surveill. Summ. 2016, 65, 1–25.

7. Subramaniam VN, Menezes AR, DeSchutter A, Lavin CJ. The Cardiovascular Effects of MJ: Are the Potential Adverse Effects Worth the High? Missouri Medicine 2019;March/April 116:2

8. Terry-McElrath YM, O’Malley PM, Johnston LD. Alcohol and MJ use patterns associated with unsafe driving among U.S. high school seniors: high use frequency, concurrent use, and simultaneous use. Journal of studies on alcohol and drugs. 2014;75:378-389.

9. Hodcroft CJ, Rossiter MC, Buch AN. CB-associated myocardial infarction in a young man with normal coronary arteries. J Emerg Med. 2014;47:277–81.

10. VelibreY, SahinS, TankO, KeskinM, BolcaO, ErenM. Acute myocardial infarction due to MJ smoking in a young man: guilty should not be underestimated. Am J Emerg Med. 2015;33:1114.e1–3.

11. Artiles, A.; Awan, A.; Karl, M.; Santini, A. Cardiovascular effects of CB (MJ): A timely update. Wiley 2019. 33:1592–1594.

12. Karschner EL, Darwin WD, McMahol RP, Liu F, Wright S, Goodwin KS, et al. Subjective and physiological effects after controlled Sativex and oral THC administration. Clin Pharmacol Ther. 2011;89:400–7.

13. Jicha CJ, Lofwall MR, Nuzzo PA, Babaloni S, Elayi SC, Walsh SL. Safety of oral dronabinol during opioid withdrawal in humans. Drug Alcohol Depend. 2015;157:179–83.

14. Desai, R.; Fong, H.K.; Shah, K.; Kaur, V.P.; Savani, S. Rising trends in hospitalizations for cardiovascular events among young CB users (18–39 years) without other substance abuse. Medicina (B. Aires). 2019;55:1–6.

15. Jouanues E, Raymond V, Lapeyre-Mestre M, Wolf V. What is the current knowledge about the cardiovascular risk for users of CB-based products? A systematic review. Curr Atheroscler Rep. 2017;19:26.

16. Sandeep Singla, Rajesh Sachdeva, JawaharL. Mehta. Cannabinoids and Atherosclerotic Coronary Heart Disease. Clin.Cardiol. 2012;35 (6):329–335(6). DOI:10.1002/clc.21962

17. Hartung, B.; Kauerstein, S.; Ritz-Timme, S.; Daldrup, T. Sudden unexpected death under acute influence of CB. Forensic Sci. Int. 2014, 237, 11–14.

18. Gunawardena MD, Rajapakse S, Herath J, Amaresa N. Myocardial infarction following CB induced coronary vasospasm. BMJ Case Rep. 2014;2014.

19. Casier I, Vanduynhoven P, Haine S, Vrints C, Jorens PG. Is recent CB use associated with acute coronary syndromes? An illustrative case series. Acta cardiologica. 2014;69:131-136.

20. I. Kotsoulou, P. Georgoulia, I. Karydas, S. Foursil, Ch. Sioka, A. Zoumbouldis, N. Demakopoulous. A rare case of myocardial infarction and ischemia in a CB-addicted patient. Clin Nucl Med. 2007 Feb; 32(2): 130-1

21. Gunawardena MDVM, Rajapakse S, Herath J, Amaresa N. Myocardial infarction following CB induced coronary vasospasm. BMJ Case Rep. 2014;2014.

22. Stanley, C.; O’Sullivan, S.E. Vascular targets for cannabinoids: Animal and human studies. Br. J. Pharmacol. 2014, 171, 1361–1378.

23. Richards, J.R.; Bing, M.L.; Moulin, A.K.; Elder, J.W.; Robert, T.; Summers, P.J.; Laurin, E.G.; Richards, J.R.; Bing, M.L.; Moulin ,A.K.; etal. CB use and acute coronary syndrome. Clin. Toxicol. 2019;56;350:831–841.

24. Draz, E.L.; Oreby, M.M.; Elsheikh, E.A.; Khedr, L.A.; Atlam, S.A. MJ use in acute coronary syndromes. Am. J. Drug Alcohol Abuse. 2017; 43: 576–582.

25. Orsini, Blaau, Blaau, Rajayer, Gurung, Tam, Morante, Shamban, Malik. Prolonged cardiac arrest complicating a massive ST-segment elevation myocardial infarction associated with MJ consumption. J Community Hosp Intern Med Perspect. 2016; https://doi.org/10.3402/jchimp.v6i31695.

26. Ghanem M, Belhadi L, Tritar A, et al. (CB and acute coronary syndrome with ST segment elevation). Ann Cardiol Angeiol (Paris). 2013;62:424–428.

27. Baily C, Merceron O, Hammoudi N, Dorent R, Michel PL. CB induced acute coronary syndrome in a young female. International journal of cardiology. 2010;143:e4-6.
34. Lee JD, Schatz D, Hochman J. CB and Heart Disease. Journal of the American College of Cardiology. 2018;71:2552.

35. Reis, J.P.; Auer, R.; Bancks, M.P.; Goff, D.C., Jr.; Lewis, C.E.; Fletcher, M.J.; Rana, I.S.; Shikany, J.M.; Sidney, S. Cumulative lifetime MJ use and incident cardiovascular disease in MiddleAge: The Coronary Artery Risk Development in Young Adults (CARDIA) study. AJPH Res. 2017; 107: 601–606.

36. Latif Z, Garg N. The impact of marijuana on the cardiovascular system: a review of the most common cardiovascular events associated with marijuana use. Journal of clinical medicine. 2020 Jun;9(6):1925.

37. Kariyanna, P.T, Wengrofsky P, Jayarangaiyah A, Haseeb, S. MJ and cardiac arrhythmias: A scoping study. Int. J. Clin. Res. Trials. 2019;4:1–11.

38. Singh,A, Saluja,S, Kumar,A, Agrawal S. Cardiovascular complications of MJ and related substances: A review. Cardiol. Ther. 2018;7:45–59.

39. Frost L, Mostofsky E, Rosenbloom J.I. MJ use and long term mortality among survivors of acute myocardial infarction. Am. Heart J. 2013;165:170–175.